BioSpace News Archive

BioCorRx Inc. announced today that it has filed a patent application with the Russian Patent Office (Rospatent) for a biodegradable implant including naltrexone.

Genesis Biotechnology Group ® (GBG) and Contract Research Organization (CRO) announced today that it has acquired BioBlocks.

BRIGHT MINDS BIOSCIENCES INC. today announced that Ian McDonald, President & CEO and Josh Blacher, VP of Corporation Development, will present live at VirtualInvestorConferences.com on October 14th.

PerkinElmer, Inc. (NYSE: PKI) announced today that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for the PKamp™ Respiratory SARS-CoV-2 RT-PCR Panel 1 assay.

Avinger, Inc. today announced that clinical data from the INSIGHT study were presented during the Late-Breaking Clinical Trials session at the VIVA conference in Las Vegas.

IsoPlexis Corporation, a leader in functional single-cell proteomics, announced the pricing of its initial public offering of 8,333,000 shares of common stock at a public offering price of $15.00 per share.

Takeda Pharmaceutical Company Limited announced the U.S. Food and Drug Administration Antimicrobial Drugs Advisory Committee voted unanimously to recommend use of maribavir for the treatment of refractory cytomegalovirus infection and disease with genotypic resistance to ganciclovir, valganciclovir, foscarnet or cidofovir in transplant recipients.

Pyxis Oncology, Inc., a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients, announced the pricing of its upsized initial public offering of 10,500,000 shares of common stock at an initial public offering price of $16.00 per share.

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today issued the following statement concerning the inadvertent issuance of an abstract by the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics (“ANE Conference”).

ProfoundBio announces that preclinical data from its novel, proprietary ADC technology platform are being presented at the 2021 Molecular Targets and Cancer Therapeutics conference hosted by the American Association for Cancer Research (AACR), the National Cancer Institute (NCI)